T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Fed’s Goolsbee Warns Inflation Remains Elevated, Signals Caution on Rate Cuts 
Gold Prices Slip Amid Iran Tensions and Rising Rate Concerns 
Wall Street Surges to Record Highs Amid Strong Earnings and Economic Stability 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Google Secures Pentagon AI Deal for Classified Projects 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
EU Warns of Response as U.S. Considers 25% Tariffs on Car Imports 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Trump Rejects Iran Proposal as Tensions Persist Amid Fragile Ceasefire 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Tokyo Inflation Slows Despite Energy Pressures and BOJ Policy Outlook 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
US Stock Futures Mixed as Fed Holds Rates, Oil Prices Surge, and Big Tech Earnings Drive Market Moves 
Dollar Holds Near Two-Week High as Fed Hawkish Shift Lifts Yields, Yen Near Intervention Zone 
Namyang Dairy Product recently lost two of its leaders - chairman Hong Won Sik and CEO Lee Kwang Bum this week. The two decided to leave over the controversies created by the company’s claim about the effectiveness of its Bulgaris yogurt in fighting COVID-19 symptoms.
The controversy that led to Namyang’s heads exit
Chairman Hong Won Sik stepped down on Tuesday, May 4, and he announced his departure through a press conference. CEO Lee Kwang Bum also left his job on Monday, and their exit came two days after Namyang Dairy’s offices were raided by the authorities as it investigates the COVID-19 false claims.
The two resigned three weeks after the company held a symposium and announced that its Bulgaris yogurt effectively lowers the chance of contracting COVID-19 by at least 77%. However, the South Korean Ministry of Food and Drug Safety called out Namyang for such doubtful claims and immediately launched an investigation.
The public reportedly flocked to grocery stores to buy Namyang’s Bulgaris yogurts, and the company experienced a surge in its shares. This is another reason why a probe has been launched.
New scandal besetting the dairy company
Now, while the yogurt controversy is not yet over, The Korea Times reported that Namyang is facing a new issue. This time it has something to do with a patent infringement violation.
The outlet reported that Namyang’s Inner Care yogurt drink comes with a supplement pill. This is placed in the cap so it can easily be taken when drinking the yogurt. However, the company’s rival, Korea Yakult, that sells MPRO3, which is a probiotics beverage, claimed that the yogurt and pill combination was imitated by Namyang from them.
MPRO3 also comes with a supplement, and Yakult Korea is claiming that they are the originator of this product that was first launched in 2019. On the other hand, Namyang’s Inner Care was only released in February.
With the identical special features between Inner Care and MPRO3, Natural Way, which has the patent rights over Yakult Korea’s design of placing the pill inside the bottle caps, filed a patent lawsuit against Namyang. It was revealed that the filing was done last month.
